The opinion concludes that ‘LANXESS CMIT/MIT biocidal product family’ is a biocidal product family within the meaning of Article 3(1), point (s), of Regulation (EU) No 528/2012, that it is eligible for Union authorisation in accordance with Article 42(1) of that Regulation and that, subject to compliance with the draft SPC, it meets the conditions laid down in Article 19(1) and (6) of that Regulation.
Recital 5, Regulation (EU) 2024/2750
In forcesince 25 Oct 2024